SCIENTIFIC BACKGROUND

ATM, BRAF, BRCA1, BRCA2, CHEK2, FANCA, PALB2, RAD51D, Fusion Genes: NTRK1, NTRK2, NTRK3

Prostate carcinoma (PCa) is the most common non-cutaneous cancer in men worldwide, with about 1.6 million cases and 366,000 deaths annually. Approximately 80% to 90% of all PCa arise in the peripheral zone of the prostate, about 10% in the transition zone, and few in the other three areas of the prostate (central, anterior, around the urethra). Three stages of development have been identified: (a) intraepithelial neoplasia, which can be considered precancerous and is characterized by hyperplasia of luminal cells and progressive loss of basal cells; (b) adenocarcinoma androgen-dependent (divided into two stages: latent and clinical), characterized by complete loss of basal cells and luminal phenotype: At this stage, the tumor is androgen-dependent and its growth can be controlled by androgen deprivation; and (c) adenocarcinoma androgen-independent (or castration-resistant).

 

GENOMIC ALTERATIONS AND POSSIBLE THERAPIES

With early diagnosis and treatment, patients have a good prognosis. Treatment of PCa depends on the grade, stage, and age and ranges from active surveillance to a mixture of surgery, chemotherapy, radiation, and/or androgen deprivation therapy (ADT). ADT is often used in combination with surgery or radiation, and often in combination with chemotherapy for metastatic disease. ADT may include two approaches: surgical castration (orchiectomy) or chemical castration with drugs that target the AR pathway.

 

Although most patients initially respond well to this therapy, nearly all cases recur and progress to primary castration-resistant prostate cancer (CRPC) or metastatic CRPC (mCRPC). For example, if this resistance is based on an alteration in AR, in NCOR1/2, or in FOXA1, therapy with AR inhibitors (e.g., enzalutamide) or CYP17A1 inhibitors (e.g., abiraterone) may prolong overall survival.

 

Approximately 25% of mCRPC patients demonstrate homologous DNA repair (HRR) deficiency and may benefit from therapy with poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi).

The greatest benefit of PARPi therapy appears to be shown by mCRPC patients with a change in BRCA1 or BRCA2, whereas patients with variants in ATM and CDK12 show limited response. However, patients with CDK12 inactivation may benefit from therapy with immune checkpoint inhibitors alone or in combination with PARPi due to an increased neoantigen load. Variants in the other HRR genes have a relatively low prevalence in mCRPC. Potential combination therapy of PARPi and second-generation antiandrogens could increase response, if appropriate.

Two PARPi for the treatment of PCa have been approved by the FDA: Olaparib for mCRPC patients who have previously received a second-generation hormonal agent and have a variant in an HRR gene (BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD54L); Rucaparib for mCRPC patients who have previously received a second-generation hormonal agent or taxane chemotherapy and have a variant in BRCA or BRCA2.

 

A family history of PCa increases the risk for PCa. In addition, PCa has been associated with hereditary breast and ovarian cancer (HBOC) syndrome (due to germline variants in homologous DNA repair genes) and Lynch syndrome (due to germline variants in DNA mismatch repair genes). Indeed, approximately 11% of patients with PCa and at least one additional primary tumor in the family carry germline variants that are associated with an increased risk of cancer. Therefore, we recommend a thorough review of personal and family history for all patients with PCa and patient education.

 

TEST RECOMMENDATIONS

Guidelines recommend tumor testing for variants in HRR genes (BRCA1, BRCA2, ATM, CHEK2, PALB2, FANCA, RAD51D, CDK12) and determination of microsatellite instability (MSI) or mismatch repair status (MLH1, MSH2, MSH2, PMS2) in all men with regional or metastatic high-risk prostate cancer. In cases of high MSI (MSI-H), therapy with immune checkpoint inhibitors may be considered, as pembrolizumab has been approved by the FDA for the treatment of non-resectable or metastatic solid tumors with dMMR or MSI-H. Targeted germline testing can be linked to identify patients with family members who may be at increased risk for cancer.

 

A TMPRSS2-ERG translocation is found in approximately 15% of prostate intraepithelial neoplasia (PIN) and in approximately 50% of PCa patients. Other translocations of the ETS family have been described, TMPRSS2-ERG-positive tumors exhibit some special features related to androgen metabolism. They have increased androgen-regulated gene expression and altered intratumoral androgen metabolism, as demonstrated by decreased testosterone concentrations and increased dihydrotestosterone (DHT)/testosterone ratios. Therefore, patients with TMPRSS2-ERG-positive PCa may benefit from novel inhibitors targeting alternative DHT biosynthesis. In the future, PARPi may also play a role in PCa patients with TMPRSS2-ERG translocation because PARP1 can interact with ERG. The resulting ERG overexpression could be inhibited by PARPi and the growth of ERG-positive tumor cells slowed.

 

Approximately 15% of PCa show variants in SPOP with favorable prognosis and improved progression-free survival, especially in patients with high PSA levels before treatment. There is also evidence that SPOP-mutated PCa fail to degrade PD-L1 due to a lack of binding to PD-L1, which may support the use of immunotherapy with immune checkpoint inhibitors in these tumors.

 

TARGETED PANEL

ATM, BRAF, BRCA1, BRCA2, CHEK2, FANCA, PALB2, RAD51D, Fusion Genes: NTRK1/2/3, MSI

GENES

ATM, BRAF, BRCA1, BRCA2, CHEK2, FANCA, PALB2, RAD51D, Fusion Genes: NTRK1, NTRK2, NTRK3
How to order

LATEST ARTICLES

Cystic fibrosis (CF) is a life-threatening, progressive, inherited condition that causes severe damage to the body, primarily affecting the organs of...

Read more

Down syndrome is a genetic condition caused by the presence of an extra copy of chromosome 21. It affects physical growth, facial features, and cogni...

Read more

Every year on April 25th, DNA Day celebrates the discovery of DNA’s double helix and the advances we’ve made in understanding genetics. D...

Read more

Neurodevelopmental disorders (NDDs) have diverse genetic origins, making diagnosis challenging. A new study analyzing over 1,100 pediatric patients f...

Read more

Colorectal cancer (CRC) remains one of the most prevalent and deadly cancers worldwide, with a significant number of cases presenting at an advanced ...

Read more

Carrier screening is a genetic test designed to identify whether an individual carries a gene with changes (mutations) associated with inherited diso...

Read more

Trisomy 13, also known as Patau syndrome, is a genetic condition in which cells in the body have three copies of chromosome 13 instead of two. The co...

Read more

The human brain develops through a complex series of events, with genes carefully regulating the formation of neurons and glial cells. A recent study...

Read more

Rare diseases affect between 300 and 400 million people worldwide – more than cancer and AIDS combined [1, 2], but despite this, many people face a...

Read more

Rosalind Elsie Franklin was a brilliant and meticulous research scientist whose interdisciplinary work made fundamental contributions to various area...

Read more